{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for megestrol root_notes_note in Note (approximate match)
Status:
Possibly Marketed Outside US
Source:
AQUACID-120 by AQUA MEDICA, S.A. DE C.V.
(2020)
Source URL:
First approved in 2020
Source:
AQUACID-120 by AQUA MEDICA, S.A. DE C.V.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Sodium acetate C-11 (C-11 acetate) Injection is a radiopharmaceutical commonly used for clinical studies with positron emission tomography (PET). It is used as a PET radiotracer for imaging cancer cells via incorporation into intracellular phosphatidylcholine membrane microdomains in cancer cells. Positron emission tomography using carbon-11 acetate (AC-PET) may help find local or distant metastases from prostate cancer. C-11 acetate is taken up in proportion to fatty acid synthesis. It is also taken up proportionally to myocardial blood flow, and therefore myocardial oxygen consumption. In rodents, there is clearance from all organs except the pancreas within one hour. Tumor uptake was clearly visible in 30 minutes. In humans, more than 80% of tracer is cleared from normal tissues within 20 minutes.It is taken up in cancer within the prostate and prostate cancer metastases, however, it has been reported that increased uptake can be seen in hyperplastic and benign prostate tissues. No urinary excretion is seen. No toxic effects have been demonstrated. The ongoing clinical trial NCT01530269 is studying how this imaging test may help influence the choice and extent of initial treatments, and subsequent treatments of prostate cancer.
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333E
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Possibly Marketed Outside US
First approved in 2017
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Isobronyl acetate (an isomer of bornyl acetate) is a component of many essential oils, which was observed to be inhibitory to microorganisms. It was also shown to have sedative effect on mice after inhalation. Isobronyl acetate is mainly used in cosmetics as a flavor and fragrance agent.
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
M019
(2020)
Source URL:
First approved in 2013
Source:
21 CFR 310.545
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
First approved in 2011
Source:
NADA039402
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Melengestrol is a steroidal progestin and antineoplastic agent which was never marketed. An acylated derivative, melengestrol acetate, is used as a growth promoter in animals. Melengestrol acetate (MGA) is one of six steroidal hormone growth promoters approved for use in Canada and USA. These products are used to improve growth rate and feed efficiency, as well as to suppress estrus in beef heifers (CFIA 2008). They are not approved for use in any species other than beef cattle meant for slaughter. MGA is the only drug of its kind that is administered in animal feed, and its labelled dose in Canada is 0.4mg per heifer per day (CFIA 2008). A mandatory withdrawal of 2 days before slaughter is applied to any animal that is administered MGA.
